MeSH D009134 - spinal muscular atrophy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biogen | Nusinersen | Spinraza |  | 2017-05-30 | $1,564.4 M | Q4/23-Q3/24 |
| Novartis | Onasemnogene abeparvovec | Zolgensma |  | 2019-05-24 | $1,354 M | Q2/21-Q2/24 |
| Roche | Risdiplam | Evrysdi |  | 2021-03-26 | $1,623.688 M | Q4/22-Q3/23 |
Clinical Trials
Historical Success Rate
Phase 1
69%9/13
Phase 2
36%9/25
Phase 3
53%8/15
Approved: 5Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use